Abstract
Human immunodeficiency virus 1 (HIV-1) trans-activator Tat recruits the human transcriptional coactivator PCAF (p300/CREB binding protein-associated factor) to facilitate transcription of the integrated HIV-1 provirus. We report here structure-based lead optimization of small-molecule inhibitors that block selectively Tat and PCAF association in cells. Our lead optimization was guided by grand-canonical ensemble simulation of the receptor/lead complex that leads to definition of chemical modifications with improved lead affinity through displacing weakly bound water molecules at the ligand-receptor interface.
| Original language | English |
|---|---|
| Pages (from-to) | 2285-2288 |
| Number of pages | 4 |
| Journal | Journal of Medicinal Chemistry |
| Volume | 50 |
| Issue number | 10 |
| DOIs | |
| State | Published - 17 May 2007 |
| Externally published | Yes |